Twist Bioscience Corp — fact timeline

Twist Bioscience Corp reported fiscal second quarter 2026 results: revenue $110.7 million, net income $44.0 million, EPS $0.71 per share. Guidance raised.

“expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results — Record revenue of $110.7 million in 2QFY26 ; Increase of more than 19% over $92.8 million in 2QFY25; 13th consecutive quarter of sequential growth — — Gross margin of 51.6% in 2QFY26 ; Improvement of”

Twist Bioscience Corp: Amended the Amended and Restated Certificate of Incorporation to increase authorized common stock by 100,000,000 shares and provide for officer exculpation (effective 2025-02-10).

“At the Annual Meeting, the Company’s stockholders approved amendments to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to (1) increase the number of shares of common stock of the Company authorized thereunder by an additional 100,000,000 shares and (2) provide for the exculpation of certain of the Company’s officers from liability in specific circumstances, as permitted by Delaware law (collectively, the “Charter Amendments”).”

Twist Bioscience Corp reported fiscal year 2024 results: revenue $300M to $304M. Guidance raised.

“— Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% —”

Twist Bioscience Corp reported fiscal second quarter ended March 31, 2024 results: revenue $75.3 million, net income -$45.5 million, EPS -$0.79.

“FISCAL 2024 SECOND QUARTER FINANCIAL RESULTS • Orders: Total orders received for the second quarter of fiscal 2024 increased to $93.2 million compared to $64.2 million for the same period of fiscal 2023 . • Revenue: Total revenues for the second quarter of fiscal 2024 increased to $75.3 million compared to $60.2 million for the same period of fiscal 2023 . ◦ SynBio revenue increased to $29.8 million for the second quarter of fiscal 2024 compared to $24.2 million for the same period of fiscal 2023. ◦ NGS revenue increased to $40.8 million for the second quarter of fiscal 2024 compared to $29.0 million for the same period of fiscal 2023. ◦ Biopharma revenue was $4.7 million for the second quarter of fiscal 2024 compared to $7.0 million in the same period of fiscal 2023. • Cost of Revenues: Cost of revenues for the second quarter of fiscal 2024 was $44.4 million compared to $41.7 million for the same period of fiscal 2023 . • Gross Margin: Gross margin for the second quarter of fiscal 202”

Twist Bioscience Corp shareholders approved Ratification of Appointment of Independent Registered Accounting Firm at the 2024-02-06 meeting.

“Proposal Three — Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered accounting firm for the fiscal year ending September 30, 2024 by the following votes:”

Twist Bioscience Corp shareholders approved Non-Binding, Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2024-02-06 meeting.

“Proposal Two — Non-Binding, Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers (“NEOs”) The Company’s stockholders approved, on a non-binding and advisory basis, a resolution approving the compensation of the Company’s NEOs by the following votes:”

Twist Bioscience Corp shareholders approved Election of Directors at the 2024-02-06 meeting.

“Proposal One — Election of Directors The Company’s stockholders approved the election of two directors to the Company’s Board of Directors as Class III Directors by the following votes:”

Twist Bioscience Corp reported the first quarter of fiscal 2024 ended December 31, 2023 results: revenue $71.5 million, net income Net loss attributable to common stockholders for the first quarter of fiscal 2024 was $43.0 million, or $0.75 per share, EPS $0.75 per share. Guidance raised.

“reported financial results and business highlights for the first quarter of fiscal 2024 ended December 31, 2023. "We're starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with a gross margin of 40.5%," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "In SynBio,”

James Thorburn departed as Chief Financial Officer at Twist Bioscience Corp.

“As previously reported by the Company in its Form 8-K filed on August 4, 2023 (the “Prior 8-K”), upon commencement of employment by Mr. Laponis, James Thorburn will no longer serve as the Company’s Chief Financial Officer.”

Adam Laponis was appointed as Chief Financial Officer at Twist Bioscience Corp.

“On January 5, 2024, Twist Bioscience Corporation (the “Company”) announced the appointment of Adam Laponis as the Company’s Chief Financial Officer and principal financial officer, effective January 8, 2024.”

Twist Bioscience Corp reported Full year Fiscal 2024 results: revenue $285 million to $290 million. Guidance initiated.

“— Expect revenue in the range of $285 million to $290 million for full year Fiscal 2024 --”

Twist Bioscience Corp reported Three months ended September 30, 2023 results: revenue $66.9 million, net income -$46.2 million, EPS -$0.81 per share.

“FISCAL 2023 FOURTH QUARTER FINANCIAL RESULTS • Orders: Total orders received for the fourth quarter of fiscal 2023 grew to $71.1 million compared to $62.1 million for the same period of fiscal 2022 . • Revenue: Total revenues for the fourth quarter of fiscal 2023 grew to $66.9 million compared to $57.3 million for the same period of fiscal 2022 . • Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2023 increased to $42.4 million compared to $31.6 million for the same period of fiscal 2022 . • Research and Development Expenses: Research and development expenses for the fourth quarter of fiscal 2023 decreased to $23.7 million compared to $29.6 million for the same period of fiscal 2022 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the fourth quarter of fiscal 2023 decreased to $47.4 million compared to $54.2 million for the same period of fiscal 2022 . • Net Loss: Net loss attributable to common stockholders for the f”

Twist Bioscience Corp reported Fiscal year ended September 30, 2023 results: revenue $245.1 million, net income -$204.6 million, EPS -$3.60 per share.

“FISCAL 2023 FINANCIAL RESULTS • Orders : Total orders received for fiscal 2023 grew to $264 million compared to $226.4 million for fiscal 2022. • Revenue : Total revenues for fiscal 2023 grew to $245.1 million compared to $203.6 million for fiscal 2022. • Cost of Revenues : Cost of revenues for fiscal 2023 grew to $155.4 million compared to $119.3 million for fiscal 2022. • Research and Development Expenses : Research and development expenses for fiscal 2023 decreased to $106.9 million compared to $120.3 million for fiscal 2022. • Selling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2023 decreased to $189.7 million compared to $212.9 million for fiscal 2022. • Net Loss: Net loss attributable to common stockholders for fiscal 2023 decreased to $204.6 million , or $3.60 per share, compared to $217.9 million , or $4.04 per share, for fiscal 2022. • Cash Position: As of September 30, 2023 , the company had $336.4 million in cash, cash equiva”

Twist Bioscience Corp reported the third quarter of fiscal 2023 ended June 30, 2023 results: revenue $63.7 million.

“Century Archive workflow by the end of calendar 2023. " FISCAL 2023 THIRD QUARTER FINANCIAL RESULTS • Orders: Total orders received for the third quarter of fiscal 2023 were $63.8 million compared to $59.7 million for the same period of fiscal 2022 . • Revenue: Total revenues for the third quarter of fiscal 2023 were $63.7 million compared to $56.1 million for the”

Twist Bioscience Corp announced a restructuring with charges of $9 and $11 million affecting South San Francisco and Wilsonville, Oregon facilities (approximately 270 employees worldwide, representing approximately 25% of the Company's total workforce).

“Company expects it to be substantially completed by the end of fiscal year 2023. As disclosed in the Original Report, the Company expected to incur pre-tax charges of between $9 and $11 million, consisting of cash expenditures for employee severance and related benefit costs. The Company recognized cumulative pre-tax restructuring costs of approximately”

James Thorburn changed role as Chief Financial Officer at Twist Bioscience Corp.

“On August 3, 2023, the Company and James Thorburn, the Company's Chief Financial Officer, mutually agreed that Mr. Thorburn will transition to a new role responsible for guiding the Company’s commercial scaling, operational leverage and DNA data storage business, once a new Chief Financial Officer is appointed.”

Robert F. Werner was appointed as chief accounting officer at Twist Bioscience Corp.

“appointed Robert F. Werner as the Company’s chief accounting officer and principal accounting officer, effective May 22, 2023.”

Twist Bioscience Corp reported fiscal 2023 results: revenue Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22.

“expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results – Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22 – – Orders increased to $64.2M in 2QFY23; up 17% over 2QFY22 – -- Decisive Actions to Accelerate Path to Profitability -- SOUTH SAN”

Twist Bioscience Corp reported fiscal second quarter ended March 31, 2023 results: revenue Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of, net income Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share, EPS $1.04 per share.

“Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of fiscal 2022”

Twist Bioscience Corp announced a restructuring with charges of between $9 and $11 million affecting worldwide (approximately 270 employees).

“On May 3, 2023, the Company’s board of directors approved a strategic restructuring plan, which includes a reduction in force affecting approximately 270 employees worldwide, representing approximately 25% of the Company’s total workforce. The Company expects the plan to be implemented beginning in the third quarter of fiscal year 2023 and substantially completed by the end of fiscal year 2023. The Company expects to incur pre-tax charges of between $9 and $11 million, consisting of cash expenditures for employee severance and related benefit costs.”

James Thorburn was appointed as Principal Accounting Officer at Twist Bioscience Corp.

“Mr. Thorburn will serve as the Company’s principal accounting officer until a successor to Mr. Yankton is appointed, in addition to his current role as the Company’s Chief Financial Officer.”

Kevin Yankton resigned as Chief Accounting Officer at Twist Bioscience Corp.

“On March 23, 2023, Kevin Yankton, Chief Accounting Officer of Twist Bioscience Corporation (the “Company”), provided notice of his resignation from the Company effective May 19, 2023, to pursue other interests.”

Twist Bioscience Corp shareholders approved Ratification of Appointment of Independent Registered Accounting Firm at the 2023-02-07 meeting.

“Proposal Three — Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered accounting firm for the fiscal year ending September 30, 2023 by the following votes: Votes For Votes Against Abstentions 52,003,570 17,623 47,382”

Twist Bioscience Corp shareholders approved Non-Binding, Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2023-02-07 meeting.

“Proposal Two — Non-Binding, Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers (“NEOs”) The Company’s stockholders approved, on a non-binding and advisory basis, a resolution approving the compensation of the Company’s NEOs by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 43,379,295 3,746,996 30,003 4,912,281”

Twist Bioscience Corp shareholders approved Election of Directors at the 2023-02-07 meeting.

“Proposal One — Election of Directors The Company’s stockholders approved the election of two directors to the Company’s Board of Directors (“Board”) as Class II Directors by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Keith Crandell 33,891,453 13,264,841 4,912,281 Jan Johannessen 32,240,144 14,916,150 4,912,281”

Twist Bioscience Corp reported first quarter of fiscal 2023 ended December 31, 2022 results: revenue $54.2 million, net income $41.8 million, EPS $0.74 per share.

“• Revenue: Total revenues for the first quarter of fiscal 2023 were $54.2 million compared to $42.0 million for the same period of fiscal 2022 . • Cost of Revenues: Cost of revenues for the first quarter of fiscal 2023 was $29.4 million compared to $27.1 million for the same period of fiscal 2022 . • Research and Development Expenses: Research and development expenses for the first quarter of fiscal 2023 were $31.2 million compared to $22.6 million for the same period of fiscal 2022 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the first quarter of fiscal 2023 were $42.3 million compared to $51.1 million for the same period of fiscal 2022 . • Net Loss: Net loss attributable to common stockholders for the first quarter of fiscal 2023 was $41.8 million, or $0.74 per share, compared to $45.6 million, or $0.91 per share, for the same period of fiscal 2022 .”

Twist Bioscience Corp reported the fourth quarter of fiscal 2022 results: revenue $57.3 million, net income $51.1 million, EPS $0.91 per share. Guidance initiated.

“FISCAL 2022 FOURTH QUARTER FINANCIAL RESULTS • Orders: Total orders received for the fourth quarter of fiscal 2022 were $62.1 million compared to $45.2 million for the same period of fiscal 2021 . • Revenue: Total revenues for the fourth quarter of fiscal 2022 were $57.3 million compared to $38.0 million for the same period of fiscal 2021 . • Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2022 was $31.6 million compared to $22.5 million for the same period of fiscal 2021 . • Research and Development Expenses: Research and development expenses for the fourth quarter of fiscal 2022 were $29.6 million compared to $19.4 million for the same period of fiscal 2021 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the fourth quarter of fiscal 2022 were $54.2 million compared to $38.2 million for the same period of fiscal 2021 . • Net Loss: Net loss attributable to common stockholders for the fourth quarter of fiscal 2022 wa”

Twist Bioscience Corp reported fiscal year ended September 30, 2022 results: revenue $203.6 million, net income $217.9 million, EPS $4.04 per share. Guidance initiated.

“FISCAL 2022 FINANCIAL RESULTS • Orders : Total orders received for fiscal 2022 were $226 million compared to $159.5 million for fiscal 2021. • Revenue : Total revenues for fiscal 2022 were $203.6 million compared to $132.3 million for fiscal 2021. • Cost of Revenues : Cost of revenues for fiscal 2022 was $119.3 million compared to $80.6 million for fiscal 2021. • Research and Development Expenses : Research and development expenses for fiscal 2022 were $120.3 million compared to $69.1 million for fiscal 2021. • Selling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2022 were $212.9 million compared to $135.9 million for fiscal 2021. • Net Loss: Net loss attributable to common stockholders for fiscal 2022 was $217.9 million , or $4.04 per share, compared to $152.1 million , or $3.15 per share, for fiscal 2021.”

Twist Bioscience Corp: Approved amended and restated bylaws adding proxy access provision, eliminating stockholder list inspection requirement, and addressing universal proxy rules (effective 2022-11-17).

“The Bylaws, as amended and restated (the “Restated Bylaws”), were effective immediately and include, among other things, the following changes: · adding a proxy access provision, inserted as new Section 2.13 of Article II of the Restated Bylaws, to allow a stockholder or a group of up to 20 stockholders owning at least 3% of the Company’s outstanding common stock continuously for at least three years to nominate and include in the Company’s proxy statement for an annual meeting director nominees constituting up to the greater of two individuals or 20% of the number of directors in office, provided that the stockholders satisfy the requirements specified in the Restated Bylaws; · eliminating the requirement that the list of stockholders be open to examination at meetings of stockholders to conform to recent amendments to the Delaware General Corporation Law; and · addressing matters relating to Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Universal Proxy Rules”

Patrick Finn was appointed as President and Chief Operating Officer at Twist Bioscience Corp.

“On October 25, 2022, the Board of Directors of Twist Bioscience Corporation (the “Company”) appointed Patrick Finn as President and Chief Operating Officer of the Company, effective immediately.”

Patrick Weiss departed as Chief Operating Officer at Twist Bioscience Corp.

“On April 20, 2022, Patrick Weiss notified Twist Bioscience Corporation (the “Company”) that he is stepping down as the Company’s Chief Operating Officer effective April 21, 2022.”

James Thorburn changed role as principal accounting officer at Twist Bioscience Corp.

“James Thorburn, the Company’s Chief Financial Officer, previously served as principal accounting officer and will continue to serve as Chief Financial Officer and principal financial officer.”

Kevin Yankton was appointed as principal accounting officer at Twist Bioscience Corp.

“On August 5, 2021, Board appointed Kevin Yankton, the Company’s Chief Accounting Officer, as principal accounting officer, effective August 5, 2021.”

Melissa Starovasnik was elected as Director at Twist Bioscience Corp.

“On August 5, 2021, the Board of Directors (the “ Board ”) of Twist Bioscience Corporation (the “ Company ”) elected Dr. Melissa Starovasnik to the Board, effective immediately.”